% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lux:284613,
      author       = {S. Lux$^*$ and M. Milsom$^*$},
      title        = {{EVI}1-mediated {P}rogramming of {N}ormal and {M}alignant
                      {H}ematopoiesis.},
      journal      = {HemaSphere},
      volume       = {7},
      number       = {10},
      issn         = {2572-9241},
      address      = {[Philadelphia, Pennsylvania]},
      publisher    = {Wolters Kluwer Health},
      reportid     = {DKFZ-2023-02032},
      pages        = {e959},
      year         = {2023},
      note         = {DKFZ-ZMBH Alliance / #EA:A012#LA:A012#},
      abstract     = {Ecotropic viral integration site 1 (EVI1), encoded at the
                      MECOM locus, is an oncogenic zinc finger transcription
                      factor with diverse roles in normal and malignant cells,
                      most extensively studied in the context of hematopoiesis.
                      EVI1 interacts with other transcription factors in a
                      context-dependent manner and regulates transcription and
                      chromatin remodeling, thereby influencing the proliferation,
                      differentiation, and survival of cells. Interestingly, it
                      can act both as a transcriptional activator as well as a
                      transcriptional repressor. EVI1 is expressed, and fulfills
                      important functions, during the development of different
                      tissues, including the nervous system and hematopoiesis,
                      demonstrating a rigid spatial and temporal expression
                      pattern. However, EVI1 is regularly overexpressed in a
                      variety of cancer entities, including epithelial cancers
                      such as ovarian and pancreatic cancer, as well as in
                      hematologic malignancies like myeloid leukemias.
                      Importantly, EVI1 overexpression is generally associated
                      with a very poor clinical outcome and therapy-resistance.
                      Thus, EVI1 is an interesting candidate to study to improve
                      the prognosis and treatment of high-risk patients with
                      'EVI1high' hematopoietic malignancies.},
      subtyp        = {Review Article},
      cin          = {A012},
      ddc          = {610},
      cid          = {I:(DE-He78)A012-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37810550},
      pmc          = {pmc:PMC10553128},
      doi          = {10.1097/HS9.0000000000000959},
      url          = {https://inrepo02.dkfz.de/record/284613},
}